Adhera Therapeutics (ATRX) 10-Q 24 May 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2021	May 21, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-13789
Entity Registrant Name	ADHERA THERAPEUTICS, INC.
Entity Central Index Key	0000737207
Entity Tax Identification Number	11-2658569
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Innovation Parkway
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70820
City Area Code	(919)
Local Phone Number	518-3748
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,630,709

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 1	$ 1
Total current assets	1	1
Total assets	1	1
Current liabilities
Accounts payable	2,255	2,257
Due to related party	4	4
Accrued expenses	2,394	2,112
Accrued dividends	4,460	4,083
Notes payable	6,393	6,318
Total current liabilities	15,506	14,774
Total liabilities	15,506	14,774
Stockholders’ deficit
Common stock, $0.006 par value; 180,000,000 shares designated,11,630,709 and 11,112,709 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	70	67
Additional paid-in capital	30,347	29,772
Accumulated deficit	(45,922)	(44,612)
Total stockholders’ deficit	(15,505)	(14,773)
Total liabilities and stockholders’ deficit	1	1
Series C Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series D Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series E Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series F Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Common stock, par value	$ 0.006	$ 0.006
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	11,630,709	11,112,709
Common stock, shares outstanding	11,630,709	11,112,709
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,200	1,200
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference value	$ 510,000	$ 510,000
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	220	220
Preferred stock, shares issued	40	40
Preferred stock, shares outstanding	40	40
Preferred stock, liquidation preference value	$ 12,000	$ 12,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	3,500	3,500
Preferred stock, shares issued	3,458	3,458
Preferred stock, shares outstanding	3,458	3,458
Preferred stock, liquidation preference value	$ 17,290,000	$ 17,290,000
Series F Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,200	2,200
Preferred stock, shares issued	361	361
Preferred stock, shares outstanding	361	361
Preferred stock, liquidation preference value	$ 1,805,000	$ 1,805,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses
Sales and marketing	$ 9	$ 784
General and administrative	101	539
Total operating expenses	110	1,323
Loss from operations	(110)	(1,323)
Other expense
Interest expense	(243)	(410)
Amortization of debt discount	(75)	(105)
Net loss	(428)	(1,838)
Dividends	(882)	(383)
Net Loss Applicable to Common Stockholders	$ (1,310)	$ (2,221)
Net loss per share – Common Stockholders - basic and diluted	$ (0.12)	$ (0.20)
Weighted average shares outstanding - basic and diluted	11,187,531	10,869,530

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Series F Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019					$ 65	$ (29,375)	$ (39,327)	$ (9,887)
Balance, shares at Dec. 31, 2019	100	40	3,478	361	10,869,530
Accrued and deemed dividend							(383)	(383)
Issuance of warrants with notes payable						239		239
Share based compensation						36		36
Net loss							(1,838)	(1,838)
Ending balance, value at Mar. 31, 2020					$ 65	(29,650)	(41,548)	(11,833)
Balance, shares at Mar. 31, 2020	100	40	3,478	361	10,869,530
Beginning balance, value at Dec. 31, 2020					$ 67	(29,772)	(44,612)	(14,773)
Balance, shares at Dec. 31, 2020			3,458	361	11,112,709
Accrued and deemed dividend						505	(882)	(377)
Issuance of common stock for term loan conversion					$ 3	23		26
Issuance of common stock for term loan conversion, shares					518,000
Issuance of warrants						28		28
Benefical conversion feature-term loans						19		19
Net loss							(428)	(428)
Ending balance, value at Mar. 31, 2021					$ 70	$ (30,347)	$ (45,922)	$ (15,505)
Balance, shares at Mar. 31, 2021			3,458	361	11,630,709

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash Flows Used in Operating Activities:
Net loss	$ (428)	$ (1,838)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation		36
Amortization of debt discount and fees	77	294
Non-cash interest expense	241	221
Changes in operating assets and liabilities:
Prepaid expenses and other assets		121
Accounts payable	(2)	720
Accrued expenses	66	52
Net Cash Used in Operating Activities	(46)	(394)
Cash Flows Provided By Financing Activities:
Proceeds from loans	48	500
Notes payable issuance costs	(2)	(91)
Net Cash Provided by Financing Activities	46	409
Net increase (decrease) in cash		15
Cash – Beginning of Period	1	50
Cash - End of Period	1	65
Non-cash Investing and Financing Activities:
Issuance of warrants with notes payable	28	239
Issuance of common stock for conversion of debt	26
Beneficial conversion feature	19
Accrued and deemed dividends	$ 882	$ 383

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Nature of Operations, Basis of Presentation and Significant Accounting Policies	Note 1 – Nature of Operations, Basis of Presentation and Significant Accounting Policies Business Overview Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company. In 2019, the Company was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. These efforts were primarily focused on Prestalia ® ® ® As of the date of this report, the Company is not engaged in any research, development, or commercialization activities, and is not generating any revenues from operations. To the extent that resources have been available, the Company has continued to work with its advisors to restructure our company and to identify potential strategic transactions to enhance the value of our company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to our legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the Company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to us or at all. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or for any future period. Principles of Consolidation The condensed consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. Going Concern and Management’s Liquidity Plans The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2021, the Company had cash and cash equivalents of $ 1,000 15.5 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 (Unaudited) The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 0.4 1.8 45.4 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to us or at all. General market conditions, as well as market conditions for companies in our financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, accounts receivable and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. There were no liabilities or assets measured at fair value on a recurring basis as of March 31, 2021 or December 31, 2020. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 (Unaudited) Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”) or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in shareholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature If the conversion feature is not treated as a derivative, the Company assesses whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the common stock into which it is convertible and is recorded as additional paid in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt. Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022 for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021 for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 (Unaudited) Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2021 2020 Three Months Ended March 31, 2021 2020 Numerator Net loss $ (428 ) $ (1,838 ) Dividends (882 ) (383 ) Net Loss allocable to common stock holders $ (1,310 ) $ (2,221 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 11,187,531 10,869,530 Net loss per share of common stock, basic and diluted Net loss per share $ (0.12 ) $ (0.20 ) Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share For the Three Months ended March 31, 2021 2020 Convertible notes 18,785,631 11,183,645 Stock options outstanding 387,550 2,941,350 Warrants 62,532,312 36,272,500 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 42,737,413 40,202,132 Series F Preferred Stock 4,374,978 4,086,178 Total 128,934,551 94,802,472

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 2 – Notes Payable 2019 Term Loan On June 28, July 3, July 17, and August 5, 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes (the “Notes”) in the aggregate principal amount of approximately $ 5.7 707,000 The Notes accrue interest at a rate of 12% ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 (Unaudited) The unpaid principal balance of the Notes, plus accrued and unpaid interest thereon, will mature on the earliest to occur of: (i) June 28, 2020 (subject to extension for up to ( 60 On December 28, 2019, the Company defaulted on the initial interest payment on the loan and the interest rate per annum increased to the default rate of 15% The Company recognized approximately $ 390,000 177,000 210,000 As of March 31, 2021 the Company has approximately $ 1.4 2020 Term Loan On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to purchase: (i) original issue discount unsecured Convertible Promissory Notes (the “Notes”), issued at a 10% 499,950 The maturity date is the six (6) month anniversary of the original issue date, or August 5, 2020, or such earlier date as the Note is required or permitted to be repaid as provided thereunder, and to pay interest to the Holder on the aggregate unconverted and then outstanding principal amount of the Note. Interest shall accrue to the Holders on the aggregate unconverted and then outstanding principal amount of the Notes at the rate of 10% On or after May 5, 2020 until the Notes are no longer outstanding, the Notes shall be convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price shall be the lower of: (i) $ 0.50 70% 60% 0.05 The exercise price of the Warrants shall be equal to the conversion price of the Notes, provided, that on the date that the Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the warrants of approximately $ 322,000 30,000 53,000 21,000 38,000 On June 15, 2020, the Company defaulted on certain covenants in the 2020 term loan and the interest rate reset to the default rate of 18% The Company recognized $ 20,000 12,000 105,000 25,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 (Unaudited) As of March 31, 2021, the debt discount and issuance costs for this term loan were fully amortized. The Company remains in default on the repayment of principal and interest on the notes. On March 19, 2021, the holder of the note converted $ 25,900 of interest into 518,000 shares of common stock. As of March 31, 2021, the Company has accrued interest on the note of approximately $ 74,000 . Secured Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10% original issue discount Senior Secured Convertible Promissory Note with a principal of $ 58,055 52,500 . The Note matures on the date that is the six (6) month anniversary of the original issue date. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the Note at the rate of 10% per annum, calculated on the basis of a 360-day year. The Company recorded approximately $ 14,000 in debt issuance cost to be amortized over the life of the loan using the straight-line method. On or after September 24, 2020, the Note shall be convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.02 65 50,000 203,000 The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 On August 5, 2020, the Company defaulted on certain covenants in the loan and the interest rate reset to the default rate of 18% For the three months ended March 31, 2021, the Company recognized approximately $ 2,600 No As of March 31, 2021, the debt discount and issuance costs for the loan were fully amortized. The Company remains in default on the repayment of principal and interest on the notes. As of March 31, 2021, the Company has accrued interest on the note of approximately $ 7,000 Secured Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10% original issue discount senior secured convertible promissory note with a principal of $ 111,111 , for a purchase price of $ 100,000 . The note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of then conversion price. The conversion price of the notes is subject to anti-dilution price protection and will be adjusted as a result of subsequent equity sales by the Company. On March 19, 2021, the conversion price of the notes was adjusted to $ 0.05 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. Additionally, the Company issued the noteholder 1,587,301 warrants to purchase the Company’s common stock at $ 0.08 per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $ 0.05 634,919 57,000 0.46% 262.27% .92 The Company recorded approximately $ 9,000 in debt issuance cost to be amortized over the life of the loan using the straight-line method. The note matures on April 30, 2021, or such earlier date as the note is required or permitted to be repaid. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% per annum, calculated on the basis of a 360-day year. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 (Unaudited) The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 For the three months ended March 31, 2021, the Company recognized approximately $ 4,700 in interest expense including $ 1,900 related to the amortization of debt issuance costs, respectively. For the three-month period ended March 31, 2021, the Company recognized $ 57,000 As of March 31,2021, the Company has recorded $ 111,000 19,000 1,000 Secured Promissory Note – January 2021 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10% original issue discounted Senior Secured Convertible Promissory Note with a principal of $ 52,778 , for a purchase price of $ 47,500 . The Note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of the then conversion price. 0.05 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. Additionally, the Company issued to the investor 753,968 warrants to purchase the Company’s common stock at an exercise price of $ 0.08 per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $ 0.05 301,592 27,000 0.46% 262.27% .97 The Company recorded approximately $ 2,000 in debt issuance cost to be amortized over the life of the loan using the straight-line method. The note matures on July 31, 2021, or such earlier date as the note is required or permitted to be repaid. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% per annum, calculated on the basis of a 360-day year. The Company recorded a discount related to the warrants of approximately $ 32,000 , including a discount of $ 3,000 and issuance costs of $ 1,000 based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of 0.45% 240.83% one year The Company recorded a beneficial conversion feature of approximately $ 19,000 related to the note that was credited to additional paid in capital, and reduced the carrying amount. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $ 41,000 . The Company also recorded a debt discount related to the convertible debt of approximately $ 2,000 and debt issuance cost of $ 1,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. For the year ended March 31, 2021, the Company recognized approximately $ 1,200 300 18,000 No As of March 31,2021, the Company has recorded $ 52,778 36,000 1,000

Licensing Agreements

Licensing Agreements	3 Months Ended
	Mar. 31, 2021
Licensing Agreements
Licensing Agreements	Note 3 - Licensing Agreements Les Laboratories Servier As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions). The terms of the agreement include single-digit royalty payments based on net sales and milestone payments based upon the attainment of sales thresholds. The agreement includes a termination clause pursuant to which Servier has the right to terminate the agreement in various circumstances, including, without limitation, as a result of the failure by the Company to achieve certain sales thresholds by the dates set forth in the agreement. On November 19, 2019, the Company entered into an Amendment No. 4 to the Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, which modified the agreement to delay the date by which the Company would be required to meet certain net sales milestones as set forth in the agreement. As per the license and commercialization agreement, as amended, Les Laboratories Servier may terminate the agreement if net sales of Prestalia® by the Company are below $ 1.0 On January 4, 2021, Servier terminated the licensing agreement with the Company for the commercialization of Prestalia®. No Novosom Agreements In 2010, the Company entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which the Company acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In May 2018, the Company issued to Novosom 51,988 75,000 45,000 20,000 25,000 The Company recognized no income from the agreement for the three-month periods ended March 31, 2020 or 2021. License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000 and future additional consideration for sales and development milestones. The upfront fee was contingent upon the Company obtaining a third-party consent to the agreement within ninety days of execution. As of March 31, 2021 and December 31, 2020, the Company had not obtained consent for the sublicense and has classified the upfront payment it had previously recorded as an accrued liability on its balance sheet.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. will provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA included personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA required a 90-day written termination notice in the event either party requires to terminate such services. We and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. Dr. Trieu resigned as a director of our company effective October 1, 2018. An unpaid balance of approximately $ 4,000

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders’ Equity	Note 5 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 1,000 90,000 1,200 220 3,500 2,200 Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 5,100 voting rights of 666.67 votes per share 7.50 As of December 31, 2020, and December 31, 2019, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 300 voting rights of 1,250 votes per share 4.00 5% As of December 31, 2020, and December 31, 2019, 40 Series E Convertible Preferred Stock and Warrants The Series E Preferred accrues 8% dividends per annum and are payable in cash or stock at the Company’s discretion. The Series E Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Warrants issued with Series E Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations. 30,547,267 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2021 (Unaudited) On December 11, 2020, the Company issued 121,699 10 On December 21, 2020, the Company issued 121,480 10 On March 19, 2021, the exercise price of the Series E warrants was adjusted down to $ 0.05 25,900 518,000 390,000 .016 262.27% .41 .43 The Company had accrued dividends on the Series E Preferred stock of approximately $ 4.1 and $ 3.7 million, for the period ended March 31, 2021 and December 31, 2020, respectively. Series F Convertible Preferred Shares and Warrants In July 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 308 shares of our Series F Preferred, at a purchase price of $ 5,000 per share of Series F Preferred. Each share of Series F Preferred is initially convertible into shares of our common stock at a conversion price of $ 0.50 per share of common stock. In addition, each investor received a 5 -year warrant (the “Warrants”, and collectively with the Preferred Stock, the “Securities”) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Series F Preferred purchased by such investor at an initial exercise price equal to $ 0.55 per share of common stock, subject to adjustment thereunder. The Series F Preferred accrues 8% dividends per annum and are payable in cash or stock at the Company’s discretion. The Series F Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in July 2018. The Warrants have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations. As of March 31, 2021, the Company had a total of 3,088,500 The Company received proceeds of approximately $ 1.4 million from the sale of the Securities, after deducting placement agent fees and estimated expenses payable by us of approximately $ 180,000 associated with such closing. In connection with the private placement described above, we also issued to the placement agent for such private placement a warrant to purchase 308,000 shares of our common stock. The warrant has a five-year term and an exercise price of $ 0.55 per share. On November 9, 2018, the Company entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 73 5,000 5 0.75 0.55 0.31 73,000 0.55 On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000 On March 19, 2021, the exercise price of the Series F warrants was adjusted down to $ 0.05 25,900 518,000 31,000 .016% 262.27% .46 .53 The Company had accrued dividends on the Series F Preferred stock of approximately $ 382,000 347,000 Common Stock On March 19, 2021, the Company issued 518,000 25,900 Warrants As of March 31, 2021, there were 62,532,312 warrants outstanding, with a weighted average exercise price of $ 0.07 per share, and annual expirations as follows: Schedule of Stockholders' Equity Note, Warrants or Rights Expiring in 2021 343,750 Expiring in 2022 — Expiring in 2023 33,645,847 Expiring in 2024 335,452 Expiring thereafter 28.207,263 Total 62,532,312 The above includes 61,839,829 price adjustable warrants, including the warrants issued with the 2021 term loan which are subject to adjustment based upon the final conversion price of the note. No warrants expired during the period.

Stock Incentive Plans

Stock Incentive Plans	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Incentive Plans	Note 6 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the three months ended March 31, 2021. Share-based Payment Arrangement, Option, Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2020 391,350 $ 0.58 Options granted — — Options expired / forfeited (3,800 ) 2.60 Outstanding, March 31, 2021 387,550 0.99 Exercisable, March 31, 2021 387,550 $ 0.99 The following table summarizes additional information on stock options outstanding as of March 31, 2021. Share-based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.98 1.00 383,500 2.07 $ 0.98 383,500 $ 0.98 $ 1.70 4,050 .77 $ 1.70 4,050 $ 1.70 Totals 387,550 2.06 $ 0.99 387,550 $ 0.99 During the three months ended March 31, 2021, the Company granted no stock options. Total expense related to stock options was approximately $ 36,000 As of March 31, 2021, the Company had no unrecognized compensation expense related to unvested stock options. As of March 31, 2021, the intrinsic value of stock options outstanding was zero.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Except for the events discussed below, there were no subsequent events that required recognition or disclosure. Default on Secured Promissory Note On April 30, 2021, the Company defaulted on the October 2020 term loan and the interest rate on the loan reset to 18% Issuance of Secured Promissory Note On April 16 th, 10% original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $ 66,666 60,000 . Additionally, the Company issued to the investor 800,000 warrants to purchase the Company’s common stock at an exercise price of $ 0.095 per share. Pursuant to the Note, the Company promises to pay the principal sum of the Note to the noteholder on the date that is the six-month anniversary of the original issue date, or such earlier date as the Note is required or permitted to be repaid as provided thereunder, and to pay interest to the noteholder on the aggregate unconverted and then outstanding principal amount of the Note in accordance with the provisions thereof. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the Note at the rate of 10% per annum, calculated based on a 360-day year and shall accrue daily commencing on the original issue date until payment in full of the outstanding principal (or conversion to the extent applicable), together with all accrued and unpaid interest, liquidated damages and other amounts which may become due thereunder, has been made. The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 70%

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, accounts receivable and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. There were no liabilities or assets measured at fair value on a recurring basis as of March 31, 2021 or December 31, 2020.
Convertible Debt and Warrant Accounting	Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”) or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in shareholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature If the conversion feature is not treated as a derivative, the Company assesses whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the common stock into which it is convertible and is recorded as additional paid in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022 for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021 for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2021 2020 Three Months Ended March 31, 2021 2020 Numerator Net loss $ (428 ) $ (1,838 ) Dividends (882 ) (383 ) Net Loss allocable to common stock holders $ (1,310 ) $ (2,221 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 11,187,531 10,869,530 Net loss per share of common stock, basic and diluted Net loss per share $ (0.12 ) $ (0.20 ) Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share For the Three Months ended March 31, 2021 2020 Convertible notes 18,785,631 11,183,645 Stock options outstanding 387,550 2,941,350 Warrants 62,532,312 36,272,500 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 42,737,413 40,202,132 Series F Preferred Stock 4,374,978 4,086,178 Total 128,934,551 94,802,472

Nature of Operations, Basis o_3

Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2021 2020 Three Months Ended March 31, 2021 2020 Numerator Net loss $ (428 ) $ (1,838 ) Dividends (882 ) (383 ) Net Loss allocable to common stock holders $ (1,310 ) $ (2,221 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 11,187,531 10,869,530 Net loss per share of common stock, basic and diluted Net loss per share $ (0.12 ) $ (0.20 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share For the Three Months ended March 31, 2021 2020 Convertible notes 18,785,631 11,183,645 Stock options outstanding 387,550 2,941,350 Warrants 62,532,312 36,272,500 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 42,737,413 40,202,132 Series F Preferred Stock 4,374,978 4,086,178 Total 128,934,551 94,802,472

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights	Schedule of Stockholders' Equity Note, Warrants or Rights Expiring in 2021 343,750 Expiring in 2022 — Expiring in 2023 33,645,847 Expiring in 2024 335,452 Expiring thereafter 28.207,263 Total 62,532,312

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Option, Activity	The following table summarizes stock option activity for the three months ended March 31, 2021. Share-based Payment Arrangement, Option, Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2020 391,350 $ 0.58 Options granted — — Options expired / forfeited (3,800 ) 2.60 Outstanding, March 31, 2021 387,550 0.99 Exercisable, March 31, 2021 387,550 $ 0.99
Share-based Payment Arrangement, Option, Exercise Price Range	The following table summarizes additional information on stock options outstanding as of March 31, 2021. Share-based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.98 1.00 383,500 2.07 $ 0.98 383,500 $ 0.98 $ 1.70 4,050 .77 $ 1.70 4,050 $ 1.70 Totals 387,550 2.06 $ 0.99 387,550 $ 0.99

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Net loss	$ (428)	$ (1,838)
Dividends	(882)	(383)
Net Loss Applicable to Common Stockholders	$ (1,310)	$ (2,221)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	11,187,531	10,869,530
Net loss per share	$ (0.12)	$ (0.20)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	128,934,551	94,802,472
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	66,667	66,667
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	50,000	50,000
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	42,737,413	40,202,132
Series F Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	4,374,978	4,086,178
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	18,785,631	11,183,645
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	387,550	2,941,350
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	62,532,312	36,272,500

Nature of Operations, Basis o_4

Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 1,000
Working capital	15,500,000
Net loss	400,000	$ 1,800,000
Retained earnings accumulated deficit	$ 45,400,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative)

Mar. 19, 2021USD ($)$ / sharesshares

Jan. 31, 2021USD ($)$ / sharesshares

Sep. 24, 2020$ / shares

Aug. 05, 2020

Jun. 26, 2020USD ($)

Jun. 15, 2020

May 05, 2020$ / shares

Feb. 05, 2020USD ($)

Aug. 05, 2019USD ($)

Mar. 31, 2021USD ($)

Mar. 31, 2020USD ($)

Dec. 31, 2020USD ($)

Oct. 30, 2020USD ($)$ / sharesshares

Dec. 28, 2019

Short-term Debt [Line Items]

Amortization of debt discount

$ 75,000

$ 105,000

Senior Secured Convertible Promissory Note One [Member]

Short-term Debt [Line Items]

Principal amount

$ 111,111

Debt Issuance Costs, Net

1,000

Debt instrument, effective percentage

10.00%

Interest expense

4,700

Amortization of debt issuance costs

1,900

Convertible Notes Payable, Current

$ 100,000

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.05

$ 0.07

Warrant term

11 months 1 day

Amortization of debt discount

57,000

Debt Instrument, Convertible, Beneficial Conversion Feature

45,000

Intrinsic value of the beneficial conversion feature

69,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

634,919

1,587,301

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.05

$ 0.08

Deemed dividend

$ 57,000

Unamortized Debt Issuance Expense

$ 9,000

Notes payable

111,000

Debt Instrument, Unamortized Discount, Current

19,000

Senior Secured Convertible Promissory Note One [Member] | Valuation Technique, Option Pricing Model [Member]

Short-term Debt [Line Items]

Debt discount to be amortized

6,000

Unamortized Debt Issuance Expense

5,000

Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member]

Short-term Debt [Line Items]

Fair value of warrants measurement inputs

0.46

Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member]

Short-term Debt [Line Items]

Fair value of warrants measurement inputs

262.27

Senior Secured Convertible Promissory Note Two [Member]

Short-term Debt [Line Items]

Warrant term

11 months 19 days

Deemed dividend

$ 27,000

Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member]

Short-term Debt [Line Items]

Fair value of warrants measurement inputs

0.46

Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Price Volatility [Member]

Short-term Debt [Line Items]

Fair value of warrants measurement inputs

262.27

Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member]

Short-term Debt [Line Items]

Principal amount

$ 58,055

Debt Issuance Costs, Net

$ 14,000

Debt instrument, interest rate

10.00%

Debt instrument, effective percentage

10.00%

Interest expense

2,600

0

Accured interest

7,000

Convertible Notes Payable, Current

$ 52,500

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.02

Debt conversion rate

65.00%

Debt default interest rate

18.00%

Debt Instrument, Convertible, Beneficial Conversion Feature

50,000

Intrinsic value of the beneficial conversion feature

203,000

Convertible Debt [Member] | Senior Secured Convertible Promissory Note One [Member]

Short-term Debt [Line Items]

Amortization of debt issuance costs

4,000

Debt discount to be amortized

5,000

Warrant [Member] | Senior Secured Convertible Promissory Note One [Member]

Short-term Debt [Line Items]

Debt discount to be amortized

66,000

Accredited Investors [Member] | Term Loan Subscription Agreements [Member]

Short-term Debt [Line Items]

Principal amount

$ 5,700,000

$ 5,700,000

Debt Issuance Costs, Net

$ 707,000

Debt instrument, interest rate

12.00%

Extension period for term of loan

60 days

Debt instrument, effective percentage

15.00%

Interest expense

210,000

390,000

Amortization of debt issuance costs

177,000

Accured interest

1,400,000

Accredited Investors [Member] | Securities Purchase Agreement [Member]

Short-term Debt [Line Items]

Debt instrument, interest rate

10.00%

Debt instrument, effective percentage

10.00%

Convertible Notes Payable, Current

$ 499,950

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.50

Weighted average price of common stock

70.00%

Debt conversion rate

60.00%

Conversion price adjusted for stock splits, stock combinations and similar events (in dollars per share) | $ / shares

$ 0.05

Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]

Short-term Debt [Line Items]

Interest expense

25,000

20,000

Amortization of debt issuance costs

12,000

$ 38,000

Accured interest

74,000

Amortization of debt discount

$ 21,000

105,000

Debt default interest rate

18.00%

Debt Conversion, Converted Instrument, Amount

$ 25,900

Debt Conversion, Converted Instrument, Shares Issued | shares

518,000

Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member]

Short-term Debt [Line Items]

Warrant term

5 years

Debt discount to be amortized

$ 322,000

Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member] | Convertible Debt [Member]

Short-term Debt [Line Items]

Debt Issuance Costs, Net

53,000

Amortization of debt discount

$ 30,000

Investor and lender [Member] | Senior Secured Convertible Promissory Note Two [Member]

Short-term Debt [Line Items]

Principal amount

52,778

Debt Issuance Costs, Net

$ 2,000

1,000

Debt instrument, effective percentage

10.00%

Interest expense

1,200

$ 0

Amortization of debt issuance costs

$ 300

Convertible Notes Payable, Current

$ 47,500

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.05

$ 0.07

Warrant term

1 year

Debt discount to be amortized

$ 3,000

Amortization of debt discount

18,000

Debt Instrument, Convertible, Beneficial Conversion Feature

19,000

Intrinsic value of the beneficial conversion feature

41,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.05

$ 0.08

Unamortized Debt Issuance Expense

1,000

Notes payable

52,778

Debt Instrument, Unamortized Discount, Current

$ 36,000

Debt Instrument, Convertible, Conversion Ratio

0.70

Warrants issued | shares

301,592

753,968

Investor and lender [Member] | Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member]

Short-term Debt [Line Items]

Fair value of warrants measurement inputs

0.45

Investor and lender [Member] | Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Price Volatility [Member]

Short-term Debt [Line Items]

Fair value of warrants measurement inputs

240.83

Investor and lender [Member] | Convertible Debt [Member] | Senior Secured Convertible Promissory Note Two [Member]

Short-term Debt [Line Items]

Amortization of debt issuance costs

$ 1,000

Debt discount to be amortized

2,000

Investor and lender [Member] | Warrant [Member] | Senior Secured Convertible Promissory Note Two [Member]

Short-term Debt [Line Items]

Debt discount to be amortized

$ 32,000

Licensing Agreements (Details N

Licensing Agreements (Details Narrative) - USD ($)	Dec. 23, 2019	Nov. 19, 2019	Mar. 16, 2018	May 31, 2018	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Novosom Verwaltungs Gmb H [Member] | Intellectual Property [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Common stock issued				51,988
Fair value of common stock issued				$ 75,000
Proceeds form sale of intangible asset	$ 45,000
Novosom Verwaltungs Gmb H [Member] | Intellectual Property [Member] | Upon Execution Of Agreement [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Payables on intellectual property							$ 20,000
Novosom Verwaltungs Gmb H [Member] | Intellectual Property [Member] | Achievement Of Performance Obligation [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Payables on intellectual property							$ 25,000
Les Laboratories Servier License Agreement [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Payments for royalties					$ 0	$ 0
License Of DiLA Assets [Member] | Accrued Liabilities [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Upfront payment agreement for license agreement			$ 200,000
Minimum [Member] | Les Laboratories Servier License Agreement [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Net Sales Threshold		$ 1,000,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Due to Related Parties	$ 4,000	$ 4,000

Schedule of Stockholders' Equit

Schedule of Stockholders' Equity Note, Warrants or Rights (Details)	Mar. 31, 2021shares
Equity [Abstract]
Expiring in 2021	343,750
Expiring in 2022
Expiring in 2023	33,645,847
Expiring in 2024	335,452
Expiring thereafter	28,207.263
Class of Warrant or Right, Outstanding	62,532,312

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)

Mar. 19, 2021USD ($)$ / sharesshares

Dec. 21, 2020shares

Dec. 11, 2020shares

Oct. 30, 2019USD ($)shares

Nov. 09, 2018USD ($)$ / sharesshares

Mar. 19, 2021USD ($)$ / sharesshares

Jul. 31, 2018USD ($)$ / sharesshares

May 31, 2018

Mar. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 31, 2019shares

Apr. 30, 2018shares

Aug. 31, 2015shares

Mar. 31, 2014shares

Class of Stock [Line Items]

Preferred stock, shares authorized

100,000

100,000

Stated value per share | $ / shares

$ 0.01

$ 0.01

Class of Warrant or Right, Outstanding

62,532,312

Value of stock issued after convertible securities conversion | $

$ 26,000

Warrants [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price | $ / shares

$ 0.07

2020 Term Loan [Member]

Class of Stock [Line Items]

Number of shares issued to loan holder

518,000

Accrued interest | $

$ 25,900

$ 25,900

Series E Warrants [Member]

Class of Stock [Line Items]

Class of Warrant or Right, Outstanding

30,547,267

Number of shares converted

518,000

Warrant exercise price shares upon conversion of debt | $ / shares

$ 0.05

$ 0.05

Common stock converted, value | $

$ 25,900

Warrant [Member]

Class of Stock [Line Items]

Adjustable warrants, shares

61,839,829

Series F Warrants [Member]

Class of Stock [Line Items]

Class of Warrant or Right, Outstanding

3,088,500

Warrant exercise price shares upon conversion of debt | $ / shares

$ 0.05

$ 0.05

Debt Conversion, Converted Instrument, Amount | $

$ 25,900

Debt Conversion, Converted Instrument, Shares Issued

518,000

Subscription Agreements [Member] | Warrant [Member]

Class of Stock [Line Items]

Warrant exercise price shares upon conversion of debt | $ / shares

$ 0.55

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

0.75

Subscription Agreements [Member] | Warrant [Member] | Private Placement [Member]

Class of Stock [Line Items]

Number of shares sold during period

73

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

73,000

308,000

Series B Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock designated, shares

1,000

Series A Junior Participating Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock designated, shares

90,000

Series C Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

1,200

1,200

Preferred stock designated, shares

1,200

Stated value per share | $ / shares

$ 0.01

$ 0.01

Preferred stock, shares outstanding

100

100

Series D Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

220

220

Preferred stock designated, shares

220

Stated value per share | $ / shares

$ 0.01

$ 0.01

Preferred stock, shares outstanding

40

40

Series E Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

3,500

3,500

Preferred stock designated, shares

3,500

Stated value per share | $ / shares

$ 0.01

$ 0.01

Preferred stock, shares outstanding

3,458

3,458

Number of unregistered shares issued during period

121,480

121,699

Number of shares converted

10

10

Dividends, Preferred Stock, Cash | $

$ 4,100,000

$ 3,700,000

Series F Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

2,200

2,200

Preferred stock designated, shares

2,200

Stated value per share | $ / shares

$ 0.01

$ 0.01

Preferred stock, shares outstanding

361

361

Dividends, Preferred Stock, Cash | $

$ 382,000

$ 347,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

150,000

Stock Repurchased During Period, Shares

20

Stock Repurchased During Period, Value | $

$ 100,000

Value of warrants held | $

$ 100,000

Series F Convertible Preferred Stock [Member] | Subscription Agreements [Member]

Class of Stock [Line Items]

Common stock at a conversion price, per share | $ / shares

$ 0.50

Preferred stock stated dividend rate

8.00%

Warrant term

5 years

5 years

Number of shares sold during period

308

Purchase price of preferred stock | $

$ 5,000

$ 5,000

Warrants term description

five years,

Proceeds from Issuance of Private Placement | $

$ 1,400,000

Placement agent fees and estimated expenses | $

$ 180,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price | $ / shares

$ 0.55

Value of stock issued after convertible securities conversion | $

$ 310,000

Series F Convertible Preferred Stock [Member] | Subscription Agreements [Member] | Warrant [Member]

Class of Stock [Line Items]

Warrant exercise price shares upon conversion of debt | $ / shares

$ 0.55

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

0.75

Series C Preferred Stock [Member]

Class of Stock [Line Items]

Stated value per share | $ / shares

$ 5,000

Preferred stock liquidation preference per share | $ / shares

$ 5,100

Preferred Stock, Voting Rights

voting rights of 666.67 votes per share

Common stock at a conversion price, per share | $ / shares

$ 7.50

Preferred stock, shares outstanding

100

100

Value of stock issued after convertible securities conversion | $

Series D Preferred Stock [Member]

Class of Stock [Line Items]

Stated value per share | $ / shares

$ 5,000

Preferred stock liquidation preference per share | $ / shares

$ 300

Preferred Stock, Voting Rights

voting rights of 1,250 votes per share

Common stock at a conversion price, per share | $ / shares

$ 4

Preferred stock, shares outstanding

40

40

Preferred stock stated dividend rate

5.00%

Value of stock issued after convertible securities conversion | $

Series E Convertible Preferred Stock and Warrants [Member] | Subscription Agreements [Member]

Class of Stock [Line Items]

Preferred stock stated dividend rate

8.00%

Series E Preferred Stock [Member]

Class of Stock [Line Items]

Deemed dividend | $

$ 390,000

Value of stock issued after convertible securities conversion | $

Series E Preferred Stock [Member] | Minimum [Member]

Class of Stock [Line Items]

Warrant term

4 months 28 days

4 months 28 days

Series E Preferred Stock [Member] | Maximum [Member]

Class of Stock [Line Items]

Warrant term

5 months 4 days

5 months 4 days

Series E Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Fair value of warrants measurement inputs

0.016

0.016

Series E Preferred Stock [Member] | Measurement Input, Price Volatility [Member]

Class of Stock [Line Items]

Fair value of warrants measurement inputs

262.27

262.27

Series F Preferred Stock [Member]

Class of Stock [Line Items]

Deemed dividend | $

$ 31,000

Value of stock issued after convertible securities conversion | $

Series F Preferred Stock [Member] | Minimum [Member]

Class of Stock [Line Items]

Warrant term

5 months 15 days

5 months 15 days

Series F Preferred Stock [Member] | Maximum [Member]

Class of Stock [Line Items]

Warrant term

6 months 10 days

6 months 10 days

Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Fair value of warrants measurement inputs

0.016

0.016

Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member]

Class of Stock [Line Items]

Fair value of warrants measurement inputs

262.27

262.27

Share-based Payment Arrangement

Share-based Payment Arrangement, Option, Activity (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share-based Payment Arrangement [Abstract]
Options Outstanding Beginning | shares	391,350
Options outstanding, weighted average exercise price, beginning | $ / shares	$ 0.58
Options granted | shares
Options granted, weighted average exercise price | $ / shares
Options expired / forfeited | shares	(3,800)
Options expired/forfeited, weighted average exercise price | $ / shares	$ 2.60
Options Outstanding Ending | shares	387,550
Options outstanding, weighted average exercise price, end of period | $ / shares	$ 0.99
Options Exercisable | shares	387,550
Exercisable, weighted average exercise price | $ / shares	$ 0.99

Share-based Payment Arrangeme_2

Share-based Payment Arrangement, Option, Exercise Price Range (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Numbers outstanding | shares	387,550
Weighted- Average Remaining Contractual Life (Years)	2 years 21 days
Weighted average exercise price	$ 0.99
Number exercisable | shares	387,550
Weighted average exercise price	$ 0.99
Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, lower	0.98
Range of exercise prices, upper	$ 1
Numbers outstanding | shares	383,500
Weighted- Average Remaining Contractual Life (Years)	2 years 25 days
Weighted average exercise price	$ 0.98
Number exercisable | shares	383,500
Weighted average exercise price	$ 0.98
Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper	$ 1.70
Numbers outstanding | shares	4,050
Weighted- Average Remaining Contractual Life (Years)	9 months 7 days
Weighted average exercise price	$ 1.70
Number exercisable | shares	4,050
Weighted average exercise price	$ 1.70

Stock Incentive Plans (Details

Stock Incentive Plans (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 36,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Apr. 16, 2021	Apr. 30, 2021
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		18.00%
Secured Promissory Note [Member] | Investor and lender [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	10.00%
Principal amount	$ 66,666
Secured Debt	$ 60,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.095
Debt instrument conversion price	$ 0.075
Debt instrument conversion percentage	70.00%